Erasca, Tango Therapeutics launch Phase 1/2 trial of cancer drug combination
TNGX•Erasca and Tango Therapeutics opened enrollment in a Phase 1/2 trial combining vopimetostat with ERAS-0015. The study targets two types of MTAP-deleted cancer, and its dose-escalation phase aims to determine the combination’s maximum tolerated dose.
1. Trial enrollment opens
Erasca and Tango Therapeutics opened enrollment in a Phase 1/2 trial combining vopimetostat with ERAS-0015 under their collaboration. The trial targets MTAP-deleted pancreatic cancer and RAS-mutant, MTAP-deleted non-small cell lung cancer. Tango sponsors the study, whose dose-escalation phase aims to determine the combination’s maximum tolerated dose.
